
TUBERCULOSIS SCREENING GUIDELINES



INTERPRETATION OF TUBERCULIN SKIN-TEST (PPD) RESULTS

A. >5mm is positive for:

- . Recent close contacts of persons with active TB
- . Persons with HIV infection
- . Persons with fibrotic CXR consistent with healed TB
- . Organ transplant recipients and other immunosuppressed patients

- B. \geq 10mm is positive for persons who do not meet the criteria in (A.) and who belong to one or more of the following:
- . Injection-drug users
- . Persons with other medical conditions reported to increase risk of progressing from latent to active TB (see list in Group 2 box on the reverse side)
- . Residents/employees of high-risk congregate settings (i.e. correctional institutions, nursing homes, homeless shelters, drug & alcohol treatment centers, healthcare facilities)
- . Persons recently arrived from countries having high prevalence of TB (e.g. \leq 5 years since arrival)
- . Medically underserved, low-income populations
- . Locally identified high-risk groups
- . Children of any age exposed to adults in high-risk categories

C. \geq 15mm is positive for persons with no risk factors for TB

ANERGY

- . Anergy testing is poorly standardized or can be selective (e.g. anergy or reactivity to mumps or candida may not reliably predict anergy or ability to respond to PPD).
- . Should not be routinely used as part of screening for TB even in HIV infected patients.

BOOSTER EFFECT

- . Persons with TB infection may have negative PPD when tested many years after infection
- . Initial PPD may stimulate (boost) ability to react to PPD
- . Positive reactions to subsequent tests may be misinterpreted as new infection
- . See Two-Step Testing

TWO-STEP TESTING

For baseline skin testing of adults who will be retested periodically to distinguish boosted reactions from reactions due to new infections:

- . If first test is (+), consider person infected at baseline
- . If first test (-), give second test 1-3 weeks later
- If second test (+), consider person infected at baseline
- If second test (-), consider person uninfected at baseline

QuantiFERON (QFT): The Centers for Disease Control and Prevention (CDC) Guidelines for the use of QFT in diagnosing Latent *Mycobacterium tuberculosis* Infection (LTBI) can be found in the Morbidity Mortality Weekly Report (MMWR), January 31, 2003, Volume 52, pages 15-18 (http://www.cdc.gov/mmwr/PDF/rr/rr5202.pdf). CDC states that QFT can aid in detecting *M. tuberculosis* infections among certain populations who are at increased risk for LTBI including recent immigrants from countries with a high prevalence of TB infection, injection-drug users, residents and employees of prisons and jails, and healthcare workers that, after their pre-employment assessment, are considered at increased risk for exposure to TB. CDC states that QFT may also be used for military personnel screening, hospital staff and health-care workers whose risk of prior exposure to TB was low, and U.S.-born students at certain colleges and universities. The full text of the CDC document can be found at: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5202a2.htm.

REFERENCES

- 1. Centers for Disease Control and Prevention. Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection. MMWR 2000; 49:RR-6.
- 2. American Thoracic Society/CDC. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. Am J Respir Crit Care Med 2000; 161:1376-1395.
- 3. CDC. Core Curriculum on Tuberculosis. Fourth Edition. DHHS, 2000.
- 4. ATS/CDC. Treatment of Tuberculosis and Tuberculosis Infection in Adults and Children. Am J Resp Crit Care Med 1994;149:1359-1374.
- 5. CDC. Guidelines for Using the QuantiFERON-TB Test for Diagnosing Latent Mycobacterium tuberculosis Infection. MMWR, January 31, 2003, Volume 52, pages 15-18.
- 6. American Thoracic Society/CDC/Infectious Diseases Society of America: Treatment of Tuberculosis. 2003. Respir Crit Care Med, vol.167, pp 603-662.